Xorte logo

News Markets Groups

USA | Europe | Asia | World| Stocks | Commodities



Add a new RSS channel

 
 


Keywords

2023-05-26 02:15:41| Engadget

Turns out Elon Musk's FDA prediction was only off by about a month. After reportedly denying the company's overtures in March, the FDA approved Neuralink's application to begin human trials of its prototype Link brain-computer interface (BCI) on Thursday. Founded in 2016, Neuralink aims to commercialize BCIs in wide-ranging medical and therapeutic applications from stroke and spinal cord injury (SCI) rehabilitation, to neural prosthetic controls, to the capacity "to rewind memories or download them into robots," Neuralink CEO Elon Musk promised in 2020. BCIs essentially translate the analog electrical impulses of your brain (monitoring it using hair-thin electrodes delicately threaded into that grey matter) into the digital 1's and 0's that computers understand. Since that BCI needs to be surgically installed in a patient's noggin, the FDA which regulates such technologies requires that companies conduct rigorous safety testing before giving its approval for commercial use. In March, the FDA rejected Neuralink's application to begin human trials reportedly in part due to all the test animals that kept dying after having the prototype BCI implanted. According to internal documents acquired by Reuters in December, more than 1,500 animals had been killed in the development of the Neuralink BCI since 2018. The US Department of Agriculture's (USDA) Inspector General has since launched an investigation into those allegations.  The FDA's reticence was also born from concerns about the design and function of the interface when implanted in humans. "The agencys major safety concerns involved the devices lithium battery; the potential for the implants tiny wires to migrate to other areas of the brain; and questions over whether and how the device can be removed without damaging brain tissue," current and former Neuralink employees told Reuters in March.While Neuralink has obtained FDA approval to begin its study, the company is not yet seeking volunteers. This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people," Neuralink Tweeted on Thursday. "Recruitment is not yet open for our clinical trial."  This article originally appeared on Engadget at https://www.engadget.com/neuralink-receives-fda-clearance-to-begin-human-trials-of-its-brain-computer-interface-001504243.html?src=rss


Category: Marketing and Advertising

 

Latest from this category

20.02Tunic publisher claims TikTok ran 'racist, sexist' AI ads for one of its games without its knowledge
20.02OpenAI will reportedly release an AI-powered smart speaker in 2027
20.0213-hour AWS outage reportedly caused by Amazon's own AI tools
20.02NASA targets March 6 for Artemis 2 launch to take astronauts around the Moon
20.02Ubisoft lays off 40 staff working on Splinter Cell remake, says game remains in development
20.02Engadget Podcast: Instagram on trial and the RAMaggedon rages on
20.02US website 'freedom.gov' will allow Europeans to view hate speech and other blocked content
20.02LA County lawsuit accuses Roblox of exposing children to 'grooming and exploitation'
Marketing and Advertising »

All news

20.02Stocks Higher into Afternoon on Less Global Tariff Uncertainty, US Economic Data, Technical Buying, Tech/Transport Sector Strength
20.02What Makes This Trade Great? RXT The Power of the Re-Entry
20.02Tunic publisher claims TikTok ran 'racist, sexist' AI ads for one of its games without its knowledge
20.02Can I get a tariff refund from DHL, UPS, or FedEx after the Supreme Court struck down Trumps tariffs?
20.02Tesla still has to pay $243 million over fatal Autopilot crash, judge rules
20.02BP seeking six-year union contract, extended strike notice
20.02Whether you use it or not, better public transit makes your commute better
20.02Monday's Earnings/Economic Releases of Note; Market Movers
More »
Privacy policy . Copyright . Contact form .